Grx2 Deficiency Accelerates BMSC Senescence And Senile Osteoporosis Via Cd36 S-Glutathionylation
As we age, our bones can become weaker, leading to conditions like osteoporosis. A key factor in this process is the aging of specialized cells in our bone marrow called bone marrow mesenchymal stem cells (BMSCs), which are essential for maintaining healthy bones. This research sheds light on a crucial mechanism behind this cellular aging and bone weakening.
The study found that a shortage of a protein called Grx2 plays a significant role. When Grx2 is deficient, another protein, CD36, undergoes a specific chemical change known as S-glutathionylation. This modification on CD36 has a detrimental effect: it causes BMSCs to absorb an excessive amount of fatty acids. This over-absorption leads to the accumulation of harmful fat byproducts and oxidative damage within the cells. Furthermore, this process disrupts the mitochondria, which are the powerhouses of the cells, impairing their ability to produce energy.
These combined effects accelerate the aging of BMSCs and contribute to the development of age-related bone loss. Importantly, the researchers discovered that by increasing the amount of Grx2 or by introducing a specific change to CD36 that prevents its S-glutathionylation, this harmful cycle can be broken, and the aging of BMSCs can be inhibited. This discovery offers new insights into the complex processes of skeletal aging and opens potential avenues for developing new treatments for senile osteoporosis.
Source: link to paper